NanoEcho’s basic patent approved in Canada
The basic patent for NanoEcho’s method, previously granted in Japan, Europe, and South Korea, has now been approved also in Canada. The basic patent protects the performance of a hand-held probe with the unique combination of placing an ultrasound transducer together with one or more magnets on the same device. The same patent is under examination in the United States, where the process proceeds according to plan.
NanoEcho’s system – intended to meet market requirements – is now being used in an ongoing clinical development study
NanoEcho is developing a system with the aim to offer the healthcare a more precise, simple, and cost-effective rectal cancer diagnosis. The prototype system used in the ongoing investigator-led clinical development studies has now been replaced with a system intended to meet market requirements. The first examination on surgically removed rectal cancer tissue with this system has now been performed.
A system intended to meet authority and customer requirements is now on site
NanoEcho has now successfully completed the detailed product development phase. The work has resulted in a system that has been developed to meet both the authorities’ and customers’ requirements. This system consists of parts manufactured by the company’s selected partners and key suppliers, Vermon and us4us. The system is now on site at the company’s premises in Lund, ready for integration and evaluation.
Start of an investigator-led clinical development study at Skåne University Hospital
An investigator-led clinical development study has started at Skåne University Hospital in Malmö. In this context, the first examination of resected rectal cancer tissue has been performed with the NanoEcho diagnostic system.
Scientific evidence for NanoEcho’s imaging method
An image of magnetic nanoparticles in human tissue generated by magnetomotive ultrasound is shown for the first time. The image created with NanoEcho’s prototype system in the ongoing investigator-led study at Sahlgrenska University Hospital has now been published in a peer-reviewed article (1).
Board member resigns at his own request due to medical reasons
At his own request, BG (Bengt-Göran) Svensson has chosen to leave NanoEcho’s board for medical reasons. At the same time, he announces that he is leaving all of his board assignments.
NanoEcho announces collaboration partner for the nanoparticle
NanoEcho and SPL medical have signed a Letter of Intent and initiated a cooperation on regulatory partnership and supply for the iron-oxide based nanoparticle. The aim of the collaboration is to achieve market approval for the NanoEcho indication, diagnostics of rectal cancer lymph node metastases.
Go ahead to start clinical development study at Skåne University Hospital in Malmö
NanoEcho has been cleared to start a clinical development study at Skåne University Hospital in Malmö. The ethics committee has already approved the study and recruitment of patients is planned to commence during the fall.
NanoEcho and us4us have signed a letter of intent
NanoEcho has chosen the supplier us4us and started collaboration around the development and future manufacturing of the imaging device.
A new Board has been appointed at NanoEcho – increased focus on commercialization
A new Board that reflects the Company’s development has been appointed. The newly appointed Chairman is Daniel Johnsson, former CEO and founder of, among others, Exertis Nordics, now investor and advisor. A new member of the Company’s Board is PhD and Business Coach Ann-Christin Malmborg Hager.